2. Protein Tyrosine Kinase/RTK Apoptosis
  3. c-Fms Apoptosis
  4. CSF1R-IN-22

CSF1R-IN-22 (Compound C19) is an orally effective CSF-1R selective inhibitor (IC50<6 nM). CSF1R-IN-22 enhances the secretion of CXCL9 from M2 macrophages, increases CD8+ T cell infiltration. CSF1R-IN-22 boosts anti-tumor immune responses of anti-PD-1, and induces apoptosis in tumor cells. CSF1R-IN-22 can effectively reprogram M2-like TAMs (tumor-associated macrophages) to the M1 phenotype and reshape the TME by inducing the recruitment of CD8+ T cells into tumors and reducing the infiltration of immunosuppressive Tregs and MDSCs.

For research use only. We do not sell to patients.

CSF1R-IN-22 Chemical Structure

CSF1R-IN-22 Chemical Structure

CAS No. : 2760585-35-9

Size Stock
50 mg   Get quote  
100 mg   Get quote  
250 mg   Get quote  
Synthetic products have potential research and development risk.

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

CSF1R-IN-22 Related Antibodies

Top Publications Citing Use of Products

  • Biological Activity

  • Purity & Documentation

  • References

  • Customer Review

Description

CSF1R-IN-22 (Compound C19) is an orally effective CSF-1R selective inhibitor (IC50<6 nM). CSF1R-IN-22 enhances the secretion of CXCL9 from M2 macrophages, increases CD8+ T cell infiltration. CSF1R-IN-22 boosts anti-tumor immune responses of anti-PD-1, and induces apoptosis in tumor cells. CSF1R-IN-22 can effectively reprogram M2-like TAMs (tumor-associated macrophages) to the M1 phenotype and reshape the TME by inducing the recruitment of CD8+ T cells into tumors and reducing the infiltration of immunosuppressive Tregs and MDSCs[1].

In Vitro

CSF1R-IN-22 (0-2500 nM; 1 h) significantly inhibits the activation of CSF-1R signaling pathway in BMDMs cells[1].
CSF1R-IN-22 (30-100 nM; 24 h) efficiently reprograms M2-type macrophages to M1-type macrophages in BMDMs and HMDMs cells[1].
CSF1R-IN-22 (10-100 nM; 20 h) processed M2-type macrophage supernatants significantly inhibits MC-38 and CT-26 cell viability[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

CSF1R-IN-22 Related Antibodies

Western Blot Analysis[1]

Cell Line: BMDMs cells
Concentration: 10, 30, 100 nM
Incubation Time: 1 h
Result: Dose-dependently inhibited the phosphorylation of CSF-1R and its downstream signaling mediators AKT and mTORC1.

Apoptosis Analysis[1]

Cell Line: MC-38, CT-26 cells
Concentration: 10, 30, 100 nM
Incubation Time: 20 h
Result: Processed M2 macrophage supernatant significantly increased the apoptosis rate of MC-38 and CT-26 cells, with an increase of approximately 60% in the 100 nM concentration group.
In Vivo

CSF1R-IN-22 (10,20 mg/kg; p.o.; once daily for 14 days) shows significant antitumor activity and enhanced cytotoxic T-lymphocyte (CTLs) activity in C57BL/6 mice bearing subcutaneous MC-38 tumors, with the high-dose group exhibiting etter effect than PLX3397 (HY-16749)[1].
CSF1R-IN-22 (20 mg/kg; p.o.; once daily for 14 days) shows stronger anti-tumor effects when combined with 100 μg/mouse PD-1 antibody.CXCL9 expression is significantly positively correlated with survival[1].


Pharmacokinetic Analysis in SD rats[1]

Route Dose (mg/kg) AUC0-t (ng·h/mL) t1/2 (h) Cl (L/h/kg) Vss (L/kg) Cmax (ng/mL) F (%)
i.v. 1 9126.62 1.34 0.10 0.34 / /
p.o. 10 85 939.36 2.41 0.12 / 10 867.65 94.2

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: C57BL/6 mice bearing subcutaneous MC-38 tumors [1]
Dosage: 5,10,20 mg/kg
Administration: p.o.; once daily for 14 days
Result: Inhibited tumor growth, tumor mass was significantly lower than that of the control group, and induced apoptosis. In the high-dose group, tumor volume inhibition (TGI) was 65% and 30-day survival in mice was 70%.
Increased mRNA levels of M1 macrophage markers (Nos2, Tnf, Il6, Il1) and decreased expression of M2 macrophage markers (Arg1, Chil3l, Rentla, Mrc1).
(10 mg/kg and 20 mg/kg) Significantly increased the proportion of CD3+ CD8+ T cells. Dose-dependently reduced the proportion of immunosuppressive Treg cells and myeloid-derived suppressor cells (MDSCs) in tumor tissues.
Animal Model: C57BL/6 mice bearing subcutaneous MC-38 tumors or MC-38-luc [1]
Dosage: 20 mg/kg; 100 μg/mouse PD-1
Administration: p.o.; once daily for 14 days
Result: Significantly lower tumor bioluminescence intensity in the combination dose group than in the PD-1 antibody alone or C19 alone dose groups in both models.
The combination dose group significantly increased the proportion of CD3+ CD8+ T cells and CTLs in the tumor tissue while significantly decreasing the proportion of immunosuppressive Treg cells in the MC-38 tumor model. A significant increase in the infiltration of CD8+ T cells and CTLs correlated with a significant increase in the mRNA expression of Cxcl9.
Co-administered mice had 100% survival at 70 days, and 70% overcame tumor recurrence within 91 days after reinoculation with MC-38 tumor cells.
A significant reduction in apoptosis and a significant reduction in the proportion of CD3+ CD8+ T cells following the use of CXCL9-neutralizing antibody.
Molecular Weight

392.41

Formula

C20H20N6O3
CAS No.
SMILES

CC(C)(C1=CC(NC(NC2=CC(NC/3=O)=C(C=C2)C3=C\C4=CN=CN4)=O)=NO1)C
Shipping

Room temperature in continental US; may vary elsewhere.
Storage

Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
References
  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.

CSF1R-IN-22 Related Classifications

  • Molarity Calculator

  • Dilution Calculator

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass   Concentration   Volume   Molecular Weight *
= × ×

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
× = ×
C1   V1   C2   V2
Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

CSF1R-IN-222760585-35-9c-FmsApoptosisCSF-1 receptorcolony stimulating factor 1 receptorCSF-1RCSF1RCXCL9 SecretionM2 Macrophage ReprogrammingT Cell InfiltrationAnti-Tumor Immune ResponseCancerImmune ModulationInhibitorinhibitorinhibit

Your Recently Viewed Products:

Inquiry Online

Your information is safe with us. * Required Fields.

Product Name

  

Salutation

Applicant Name *

 

Email Address *

Phone Number *

 

Organization Name *

Department *

 

Requested quantity *

Country or Region *

      

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
CSF1R-IN-22
Cat. No.:
HY-162415
Quantity:
MCE Japan Authorized Agent:

Customer Review

Thank You for Your Feedback!

Request for HNMR Report

Please fill out this form to request the QC report. We will send it to your Email address shortly.

Your information is safe with us. * Required Fields.

Product Name

  

Lot #

Applicant Name *

 

Email Address *

Phone Number

 

Department *

Organization Name *

 

Country or Region *

Remarks

SAFETY DATA SHEET (SDS)

English - EN (0 KB) Français - FR (0 KB) Deutsch - DE (0 KB) Norwegian - NO (0 KB) Español - ES (0 KB) Swedish - SV (0 KB)

Request for HNMR Report

We have received your request and will respond to you as soon as possible.